Articles tagged with Brain Tumors
Researchers discovered dasatinib inhibits growth of molecular subgroup EPN and activates anti-tumor immune responses. Treatment with dasatinib induced complete regression in 78% of animals, supporting clinical evaluation.
A recent study from Memorial Sloan Kettering Cancer Center sheds new light on the heterogeneity of GBM tumors and the role of cancer stem cells in tumor growth. The research identifies six distinct transcriptional states, each with its own unique gene signature, and provides guidance for future research to develop targeted therapies.
Researchers developed an AI model to detect brain cancer spread in surrounding tissue using MRI scans, showing 85-per-cent accuracy. This non-surgical method offers insights into patients' cancer without aggressive surgery, potentially improving treatment and survival.
Researchers at Uppsala University found that Semliki Forest virus penetrates the central nervous system by entering the cerebrospinal fluid and binding to VLDLR before penetrating deeper into the brain. This finding could be used to develop the virus as an agent for treating brain cancer.
A study suggests targeting endocan, a protein produced by endothelial cells in blood vessels, could slow tumor growth and make glioblastoma more vulnerable to existing treatments. The discovery may lead to new strategies to combat glioblastoma, which has an average lifespan of just 12-15 months.
The study found that COVID-19-related disruptions led to frequent delays in investigations or treatments for children with brain tumors. Caregivers reported feeling traumatized by their experiences, including lack of access to healthcare facilities and social situations, which made it harder to evaluate their concerns.
Scientists at the University of Plymouth are creating a humanised meningioma model to study interactions between immune cells and tumour cells, enabling the development of effective therapies for NF2-related schwannomatosis. The model will be made available worldwide to test new treatments and reduce clinical trial delays.
A phase 2 study conducted by Mayo Clinic found that 56% of participants were alive after 12 months, with a median overall survival of 13.1 months. The treatment, which combines short-course hypofractionated proton beam therapy with advanced imaging techniques, was more effective in patients over 65 with favorable tumor genetics.
Glioblastoma brain tumors synchronize their growth with the daily release of steroid hormones like cortisol, according to new research. Blocking these signals slows tumor growth and disease progression in animal models.
Scientists have created a living cell therapy that can navigate to specific organs using a
A randomized phase 3 trial found that adding temozolomide to radiation therapy improves long-term survival for adult patients with low-grade gliomas. The 10-year survival rate was 70% with combined treatment, compared to 47% with radiation alone.
A new study from UCLA Health Jonsson Comprehensive Cancer Center introduces a combined genetic and functional profiling approach to predict how glioblastoma will respond to therapy. The approach helps identify new ways to target and treat the tumors more effectively, including using an experimental drug called ABBV-155.
Researchers have trained AI models to distinguish brain tumors from healthy tissue using convolutional neural networks and transfer learning. The models achieved an average accuracy of 85.99% at detecting brain cancer, with the ability to generate images showing specific areas in its tumor-positive or negative classification.
The EMA's orphan designation for G2B-002 marks a significant milestone in the fight against pediatric brain tumors. The innovative product leverages Gate2Brain's proprietary technology to enhance drug delivery across the blood-brain barrier, promising enhanced effectiveness and safety for complex cancer treatments.
Researchers developed a new AI-powered diagnostic system, FastGlioma, which reveals invisible cancerous tissue in brain tumor surgery. The technique may delay or prevent recurrence of high-grade tumors and improve patient survival.
Researchers developed an AI-powered model called FastGlioma that can detect residual tumor tissue with high accuracy in 10 seconds. The technology outperformed conventional methods, reducing the risk of missed tumors by nearly 75%. This innovation could change the field of neurosurgery and minimize reliance on radiographic imaging.
Researchers found that non-invasive stereotactic radiosurgery significantly improves tumor control and reduces symptoms such as tinnitus, cranial nerve deterioration, and vestibular dysfunction. Early treatment can prevent tumors from growing over time and spare patients from irreversible problems.
Researchers have developed an immunotherapy that targets glioblastoma by turning its microenvironment against it. The treatment uses CAR T-cells with a blueprint for a molecule that blocks tumor signals, allowing macrophages and microglia to support the attack on cancer cells.
Glioblastoma is a deadly form of brain cancer affecting 500 Swedes annually. Researchers have identified 'foam cells' that aid tumour growth by releasing signal substances and promoting blood vessel formation.
A team of researchers at the University of Toronto has discovered two distinct subtypes of glioblastoma cancer stem cells, each with unique genetic vulnerabilities. By targeting these vulnerabilities, a more effective treatment approach may be developed, improving prognosis for patients with this lethal brain cancer.
A new genomic test using optical genome mapping (OGM) technology will enable faster and more comprehensive diagnosis of brain tumors in children. This innovative approach will help identify novel structural variants that could lead to improved outcomes and new targets for treatment.
A study published in Science Advances has identified key characteristics of multiply recurrent meningiomas (MRMs), a highly aggressive form of brain tumor. Researchers found that MRMs are more numerous, larger and more common in men than women, with increased chromosomal instability and DNA methylation.
Glioblastoma, the most malignant primary brain tumour, has an 18-month median survival rate despite treatment. New research from the University of Ottawa suggests a drug used to slow ALS progression may also suppress glioblastoma's self-renewing cancerous stem cells.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Children who survived childhood brain cancer are more likely to struggle academically, with a greater chance of being held back and performing poorly on state testing. The study's findings highlight the need for better support and resources to help these students succeed.
A recent clinical trial analysis found that patients with truly unmethylated MGMT promoter do not benefit from temozolomide treatment, challenging current treatment protocols. This study aims to transform the treatment landscape for older adults glioblastoma patients by identifying biomarkers for more personalized therapies.
Researchers evaluated the efficacy and safety of using Zika virus for treating CNS tumors, finding that it reduces cell viability, inhibits growth, and decreases Bcl2 expression, potentially enhancing chemotherapy and radiotherapy effects. This ultimately led to significant tumor remission and improved long-term survival through an enh...
A study by Ohio State University researchers found that combining pimozide with CB-839 can effectively suppress glioblastoma growth by blocking lipid production and starvation of tumor cells. This innovative combination may also hold promise for treating other cancers relying on glutamine and lipids.
A study by Osaka Metropolitan University found that ChatGPT's diagnostic performance for brain tumors was comparable to that of neuroradiologists, with an accuracy rate of 73%. The model's performance varied depending on the type of clinical report written, with higher accuracy when using reports from neuroradiologist writers.
A new microscope-integrated OCT system has been developed to identify tumor margins during brain surgery, providing high-resolution images of subsurface anatomy. The system has shown promising results in clinical studies, with the potential to improve outcomes for neurosurgery procedures.
A phase II clinical trial found that radiopharmaceuticals, specifically 177Lu-Dotatate, can extend progression-free survival for patients with refractory meningioma by nearly 80% after six months. The therapy offers a safe and effective treatment option for those with aggressive tumor growth.
Researchers at UNIGE and HUG have developed CAR-T cells capable of targeting malignant gliomas while sparing healthy tissue. The treatment uses a specific marker on tumour cells and appears to be effective in controlling tumour growth without signs of toxicity.
Researchers created an artificial blood vessel model using 3D bioprinting to test new therapies for glioblastoma. This device enables the creation of personalized disease models, potentially improving patient survival rates.
Researchers at ETH Zurich have found an antidepressant, vortioxetine, effective against glioblastomas, a particularly aggressive brain tumor with no cure. The drug's ability to cross the blood-brain barrier and trigger a signalling cascade makes it promising for treating this deadly tumour.
A new Northwestern Medicine study identifies critical language connector sites in the cerebral cortex that work together to produce language. These sites serve as connectors between subnetworks of people, serving a similar function for language in the brain.
This study presents an advanced U-net segmentation model for brain tumor MRI image segmentation, which incorporates residual grouped convolution and attention mechanisms. The proposed model achieves improved feature extraction ability and segmentation accuracy, resulting in better performance than traditional CNN methods.
A trial at UT Health San Antonio found that Sacituzumab Govitecan was well-tolerated and showed signs of effectiveness for patients with breast cancer who had progressed to brain tumors. The drug has been shown to deliver a topoisomerase inhibitor into tumors, providing promising clinical signals of efficacy.
A new study reveals that Meteorin-like protein saps energy from T cells, severely limiting their ability to fight cancer. By understanding this signaling pathway, researchers may be able to develop targeted treatments to restore metabolic health and enhance the immune system's power against tumors.
A new study has shown that a drug developed for pancreatic cancer is effective in treating the most aggressive form of medulloblastoma, a childhood brain tumor. The drug, Minnelide, reduced tumor growth and increased the efficacy of chemotherapy, offering hope for improved survival rates for children with this disease.
Researchers discovered that serotonin-producing neurons slow tumor growth by regulating histone serotonylation, while other neural circuits promote tumor growth. Restoring neurotransmitter levels also slows down tumor progression.
Scientists found islands of highly potent immune cells in the bone marrow close to glioblastoma tumors, which play a central role in defending against cancer. This discovery may lead to innovative therapies and could improve patients' chances of survival.
Scientists used AI to identify genes that can convert brain cancer cells into immune cells, increasing survival chances by up to 75% in mouse models. The approach bypasses the blood-brain barrier, offering new hope for aggressive cancers.
Researchers found that hyperactivated neurons drive cancer proliferation and that serotonin uptake by ependymoma cells promotes tumor growth. Inhibiting this process blocked tumor growth, opening doors for drug discovery.
Scientists discovered that Tumour Treating Fields (TTFs) improve Natural Killer cell killing by increasing degranulation, a sign of better cell function. The findings offer promising implications for treating glioblastoma and other cancers.
Researchers at NYU Abu Dhabi have discovered that the tumor suppressor protein Par-4 can cause a unique type of cell death called ferroptosis in human glioblastoma cells, while sparing healthy cells. This new understanding has the potential to inform the development of novel treatments for various hard-to-treat cancers and neurodegener...
Researchers have developed a new technique called burst sine wave electroporation (B-SWE) that can disrupt the blood-brain barrier around brain tumors without causing significant damage to healthy tissue. This method shows promise for treating aggressive brain cancers like glioblastoma, which currently have limited treatment options.
A team of researchers has created a molecular atlas of the human brain's vasculature, revealing how endothelial cells regulate interactions between the bloodstream and surrounding tissues. The study provides insights into the growth patterns of blood vessels in early development, adulthood, and disease stages.
Researchers at the University of Plymouth have discovered that administering a HDAC6 inhibitor prior to radiotherapy can inhibit cellular growth and increase cell death in meningioma samples. This promising approach could lead to improved treatment outcomes for malignant meningioma patients.
The study provides a detailed analysis of high-grade glioma molecular characteristics, revealing shifts in gene expression and tumour microenvironment. Longitudinal samples revealed unique opportunities to observe tumour evolution, shedding light on genetic and epigenetic events associated with recurrent disease.
Scientists at Baylor College of Medicine have discovered specific 3D genome features called TULIPs in the DNA of posterior fossa group A (PFA) ependymoma, a type of brain tumor commonly diagnosed in young children. These features are unique to PFA ependymoma and could be targeted for new treatments.
Researchers identified a population of stem-like cells that initiates and maintains Group 3 medulloblastoma (Gr3-MB) in the developing brain. Eliminating these cells led to tumor shrinkage in preclinical models, suggesting a novel approach for treating children with Gr3-MB.
Researchers have developed a minimally invasive surgical technique to remove lesions in the skull base region, reducing damage to the brain and preserving neurological functions. The endoscopic approach results in shorter operative times and less blood loss compared to conventional microscopic surgery.
Researchers have developed procedures for using gold nanostars to perform more efficient, conformal, and safe laser ablations for treating brain tumors. This technique addresses limitations in traditional LITT by providing improved precision for lesions greater than 3 cm or with complex shapes.
Scientists are conducting a clinical trial to explore the use of anti-retroviral medications Ritonavir and Lopinavir as a potential treatment for brain tumors in patients with Neurofibromatosis 2. The study aims to determine if these drugs can help reduce tumor growth and survival in NF2 patients.
Researchers at Linköping University and the Medical University of Graz have developed a new cancer treatment using an iontronic pump to deliver continuous, low-dose chemotherapy directly to brain tumors. This approach significantly reduces tumor growth by bypassing the blood-brain barrier, a common obstacle to effective treatment.
Researchers developed a rapid genotyping test for patients with central nervous system lesions, detecting key mutations associated with brain cancers in samples taken during a lumbar puncture. The test eliminated the need for surgical brain biopsies in seven cases and significantly accelerated time to treatment, from an average of 12 d...
Researchers at the University of Michigan Health Rogel Cancer Center discovered that pediatric DIPG tumors have a distinct metabolic pathway that allows them to evade treatment. By inhibiting this pathway, radiation therapy became effective in killing cancer cells.
Researchers developed a novel immunotherapy approach using ultrasound to deliver chemotherapy and antibodies to the brain, boosting immune system recognition of glioblastoma cells. The treatment showed promise in improving responses to PD-1 blockade in patients with advanced brain tumors.
A new surgical platform using mass spectrometry identifies key gene mutations in brain cancer, including IDH mutations, during surgery. This allows for rapid diagnosis, prognosis, and tumor resection to improve patient outcomes.
A new study using next-generation molecular sequencing and DNA methylation profile analysis identified a rare type of pediatric brain tumor with specific genetic alterations. The tumors were found to be clinically aggressive but some responded well to chemotherapy, highlighting the need for personalized treatment strategies.